The FDA on November 17, 2021, approved KEYTRUDA® (Pembrolizumab) for the adjuvant treatment of patients with Renal Cell Carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. KEYTRUDA® is a product of Merck & Co.
Bottom Ad
Advertisement
Subscribe
